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The discovery that collateral development after progressive 
coronary stenosis proceeds by means of DNA synthesis, 
mitosis and proliferation of endothelial and smooth muscle 
cells in preformed small interconnecting arterioles (canine 
heart) and capillaries (porcine heart) has stimulated re- 
search into the molecular mechanisms of vascular growth. 
Growth is tightly controlled under physiologic conditions, 
and several factors must act in concert to overcome control. 
Because the result of growth is a much larger orderly 
structure of complex design, we expect the existence of a 
genetic blueprint for its construction. 
Peptide growth factors have recently been isolated from 
a variety of organs, including the heart. We have provided 
experimental evidence that the heparin-binding growth fac- 
The most interesting aspect of coronary anastomoses is their 
ability to respond with growth when the large epicardial 
arteries become stenosed and occluded and the tissue be- 
comes potentially ischemic. This growth adaptation can be 
very efficient, and cases have been described in which 
chronic occlusion of the left main coronary artery was 
tolerated without infarction. Several reports (1,2) have 
shown that regional left ventricular wall function was pre- 
served in the presence of proximal left anterior descending 
coronary artery occlusion. Collateral flow adaptation is not 
always that efficient, and acute myocardial infarction is not 
only a consequence of coronary occlusion, it is also a 
consequence of failure of the collateral circulation. 
Several reasons for failure of collateral vessels to prevent 
infarction are known. The most important is probably the 
time factor: if a coronary artery that is only minimally 
stenosed becomes acutely occluded, the growth adaptation 
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tor beta-ECGF shows an increased transcription in growing 
pig collateral vessels. Because the chain of events probably 
originates in the ischemic cardiac myocyte, it appears logical 
to search there for the initiating factor. In addition to local 
production, growth factors can also be transported into 
ischemic myocardium by blood-borne cells. Monocytes ad- 
here to altered endothelium in a potentially ischemic region 
and start to produce growth factors in situ. Platelets are rich 
sources of transforming growth factor-beta (TGF-/I), plate- 
let-derived endothelial cell growth factor (PDECGF) and 
platelet-derived growth factor (PDGF), all of which are 
known angiogenic factors or mitogens. 
(J Am Co11 Cardiol1990;15:513-8) 
of collateral vessels cannot occur because they require 
approximately 24 h of response and about 3 days to comple- 
tion. If acute thrombosis of coronary arteries can be pre- 
vented in the future by medication and changes in life-style, 
the collateral circulation is certainly able to prevent infarc- 
tion in many more patients than previously thought possible. 
If we understood the process of coronary angiogenesis 
better, we might be able to support it in the future with new 
medicines. 
Laboratory Models of Collateral 
Vessel Growth 
Long-term coronary artery occlusion by ameroid constric- 
tor. We studied (3) slowly progressing coronary artery 
occlusion in dogs and pigs after long-term implantation of 
ameroid rings. These rings consisted of a hygroscopic plastic 
material (originally casein hardened with formalin) that 
swells and compresses the artery. The rings were originally 
encased by a band of stainless steel to prevent outward 
swelling, but we recently simplified this procedure by using 
a strong ligature instead of the steel ring because it does not 
produce a shadow for in vivo coronary angiography. De- 
pending on its (somewhat controllable) ability to absorb 
water, the ameroid occluded the artery at approximately 17 
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days (range 12 to 21). However, swelling of the constrictor 
by water uptake does not fully explain coronary artery 
occlusion. The formation of platelet thrombi within the 
stenosed and poststenotic segments contributes to the com- 
pletion of the stenosis and may cause sudden death. The 
foreign body reaction around the constrictor and its subse- 
quent shrinkage may also contribute to complete occlusion. 
Sixty-six percent of dogs with occlusion of the left circum- 
flex artery plus the right coronary artery by this method 
survived. Death in the other 33% was caused by acute 
ventricular fibrillation. 
whether repeated brief occlusions are the most efficient 
method for eliciting these factors because it can be argued 
that most of what was produced during ischemia may get lost 
during the subsequent periods of reactive hyperemia and 
normoxia. The procedure may also cause various adaptations 
other than collateral vessel growth (for example, “stunning,” 
“preconditioning” or enzyme induction) as well as changes in 
the concentration, synthesis and breakdown of adenosine 
triphosphate (ATP), glycogen, lipids and the like. 
The predominant left coronary artery branch in the pig is 
the left anterior descending artery, followed in importance 
by the right coronary artery. A proximal occlusion of the left 
anterior descending or right coronary artery in the pig by 
ameroid constrictor is poorly tolerated. Although mortality 
is not excessively higher than in the dog, a large infarct 
develops and complicates the interpretation of collateral 
vessel development because the vascular growth processes 
of wound healing may differ from those of collateral vessel 
growth. The response of the pig heart is markedly influenced 
by the almost complete lack of collateral vessels in contrast 
to the dog, in which collateral blood flow can be 30% of the 
normal blood flow at rest. Therefore, in our experiments in 
pigs, we occluded the left circumflex coronary artery, which 
is the smallest of the three epicardial arteries in the pig, and 
placed the constrictors downstream from the first marginal 
branch. This procedure resulted in a 30% mortality rate from 
ventricular fibrillation, and about 50% of the survivors were 
free of macroscopic infarcts. 
The most important advantage of this method is its ability 
to produce collateralJiow without infarction. Repeated 2 min 
periods of ischemia do not cause necrosis. Tissue necrosis 
(often as focal mini-infarcts) is a complicating factor in 
ameroid occlusion because angiogenesis after wound healing 
may differ from the process of collateral vessel growth. Our 
experience with this method in pigs (5) was not particularly 
encouraging. Although we followed the Franklin protocol of 
a 2 min occlusion every 30 min, 8 h/day, 5 days/week for 4 
weeks and for up to 400 occlusions, many animals died 
because of reperfusion ventricular fibrillation. The long-term 
implants and the irritation they caused led to adhesions that 
by themselves produced ingrowth of vessels that served as 
collateral vessels. The same result was achieved after 4 weeks 
whether or not the cuff was occluded, PS just described. 
Vascular Growth as the Underlying Principle 
of Collateral Flow Adaptation 
Often-repeated brief occlusions. Utilizing a method devel- 
oped in Dean Franklin’s laboratory, Yamamoto et al. (4) 
employed brief coronary occlusions (2 min, once every 30 
min) produced with a chronically implanted inflatable cuff. 
After about 100 occlusions in the dog, an occlusion did not 
produce changes in regional contractility, and it was not 
followed by a reactive hyperemia response. A plausible 
explanation would be to assume that the collateral vessels 
had formed. On the basis of radioactive tracer microspheres 
and postmortem angiograms, this was later shown to be the 
case. An important conclusion from this experiment was that 
a relation exists between the number of collateral vessels 
already present before the start of repetitive occlusions and 
the number of occlusions necessary to produce collateral 
flow. More occlusions were needed in animals with no or 
only a few original collateral vessels. Dogs with few original 
collateral vessels needed more occlusions than did dogs with 
many original collateral vessels. 
When dogs at the critical stage of ameroid-induced coro- 
nary stenosis receive the metaphase poison colchicine, nu- 
merous mitoses of endothelial and smooth muscle cells can 
be observed in excised and visibly enlarged collateral vessels 
(but not in normal coronary arteries of the same size). When 
animals receive tritiated thymidine during collateral vessel 
development, numerous nuclei contain radioactive deoxyri- 
bonucleic acid (DNA) that can be detected by autoradiogra- 
phy (3). Experiments with a remote-controlled mercury- 
filled coronary constrictor cuff have shown (6) that, if the 
time from onset of coronary narrowing to complete occlu- 
sion is 3 days, endothelial cells have the most frequently 
labeled nuclei, followed by adventitial fibroblasts and 
smooth muscle cells. If the time from onset of narrowing to 
occlusion is 6 days, the vascular smooth muscle is the most 
heavily labeled, followed by adventitial fibroblasts and endo- 
thelium. From these experiments, we concluded that the 
endothelium leads the process of growth adaptation and that 
smooth muscle follows. An endothelial-smooth muscle inter- 
action process is very likely and should be studied. 
Another important conclusion was that the ischemic In ameroid occlusion, thymidine-labeled vascular cells are 
stimulus had to be of a certain intensity to cause an effect. A most frequent at approximately 3 weeks after implantation of 
15 s occlusion every 2.5 min was ineffective, although the the constrictor, which corresponds to about 3 days after 
amount of occlusion time per hour was the same. It is complete occlusion, and labeling decreases sharply thereafter 
assumed that the intensely ischemic myocardium produces (7). At 8 weeks after implantation (which is about 5 weeks 
certain factors responsible for collateral vessel growth. The after occlusion), the labeling index is low but still significantly 
nature of these factors is unknown. It is also unknown above that of control tissue from the same heart. 
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In porcine hetwrs, occlusion of the distal left circumflex 
coronary artery also leads to a marked increase of the 
thymidine-labeling index (8). In contrast to our findings in 
dogs, the index was increased in the entire heart. but 
significantly more so in the region at risk of &hernia. In the 
porcine heart, collateral vessel growth additionally differs in 
that all classes of vessels in the entire risk region participate 
in the growth process (that is, nuclei of all classes of vessels 
are labeled) and morphometric studies (9) show increases in 
the total luminal area of most classes of small vessels. 
Comparison With the Human Heart 
Based on systematic studies by Fulton (10) and coronary 
cineangiography. general agreement exists that in human 
coronary artery disease, a subendocardial plexus of collat- 
eral vessels develops and links the region at risk of infarction 
with its better perfused adjacent regions. The appearance of 
this plexus in postmortem tomoangiograms is that of an 
increased density of injected small vessels. The response of 
the porcine heart to progressive coronary occlusion appears 
very similar: a dense blush of injected microvessels appears 
throughout the thickness of the left ventricular wall and is 
somewhat more prominent subendocardially than near the 
subepicardium. This is probably the angiographic correlate 
of the generalized vascular growth response to ischemia in 
the porcine heart ( I I). In the human heart, coronary angiog- 
raphy performed either in vivo or after death sometimes 
reveals larger anastomoses at or near the epicardium than in 
the endocardium. Large anastomoses often traverse the atria 
in the diseased human heart, thereby connecting proximal 
with distal segments of the same occluded coronary artery. 
or they connect branches of the right with those of the left 
coronary artery. In the porcine heart, larger collateral ves- 
sels are not detectable on the epicardial surface. but some- 
times one or more macroscopically visible anastomoses 
traverse the posterior papillary muscle (12). 
From these ohsenw~ions kt’e tan stq rhtrt neifhcr the 
porcine nor the canine coronary mtery system complt~tcly 
resen~hlrs the prrttern of t~ollcr~erali~ation of’ the humtrn 
heart. The contribution of numerous small precapillary 
vessels, similar in pig and human but completely absent in 
the canine heart, makes the pig a somewhat more relevant 
model than the dog. However, the dog heart has served as a 
valuable model to work out the stages of growth adaptation 
in response to progressive occlusion. The dog model may 
also help explain the developments of large epicardial anas- 
tomoses in humans. 
Role of Growth Factors Versus Physical 
Forces in Collateral Vessel Enlargement 
In the 1960s and 197Os, the stimulus for vascular growth 
was believed to be of physical nature. Changes in pressure 
gradients with the progression of stenosis (13). changes in 
SCHAPER ET AL. 515 
MOLECULAR BIOLOGY OF CORONARY ANASTOMOSES 
the flow velocity and viscous drag (14) acting on the endo- 
thelium and on the entire vessel wall and changes in tangen- 
tial wall tension brought about by ischemic vasodilation (15) 
were all believed to act as triggers of growth. In 1972, we (3) 
postulated that the increased mechanical stress acting on the 
cell membrane must be transduced to the nucleus to respond 
with mitosis, but the detailed pathway was not apparent at 
that time. The change in our attitude toward primarily 
biochemical transmitters of growth occurred when we eval- 
uated the thymidine-labeling index in tissue sections after 
graded steps of stenosis (6): a small but significantly in- 
creased label incorporation was also observed in veins near 
more heavily labeled arterioles. Because physical forces 
differ greatly between arteries and veins. a nonphysical force 
must have been active. 
Growth Factors Can Be Carried Into 
Ischemic Tissue by Blood Cells 
Growth factors (that is, mitogenic peptides) can be iso- 
lated from the heart (16), but uncertainties exist with regard 
to their physiologic and pathophysiologic role and to 
whether those that become active in the tissue after progres- 
sive coronary stenosis were produced on site. released from 
storage sites or carried into the tissue by growth factor-laden 
cells (platelets) or by growth factor-producing cells (mono- 
cytes-macrophages). 
Role of platelet invasion. We (17.18) have observed the 
invasion of transforming vascular walls by monocytes and 
platelets. Platelets are a particulairy rich source of growth 
factors. The smooth muscle mitogen platelet-derived growth 
factor (19). the endothelial mitogen platelet-derived endothe- 
lial cell growth factor (PDECGF) (20) and the nonmitogenic 
but angiogenic transforming growth pdctor (TGF-P) (21) have 
all been isolated from platelets. Although it may be expected 
that platelets and their growth factors play an important role 
in collateral vessel growth, the invasion of platelets into the 
wall of collateral vessels is only infrequently observed. 
Platelet invasion occurs mainly at vascular segments that 
appear markedly damaged and where other blood elements 
like extraluminal erythrocytes are also present. 
Role of monocytes-macrophages. Because vascular 
growth also occurs in nondamaged vascular segments and 
because intraluminal platelet aggregates are uncommon in 
the collateral vessels themselves, we doubt a very prominent 
role of platelet-derived growth factors. However, a coronary 
stenosis upstream may cause a “showering” of aggregated 
platelets that are then lysed in the microvasculature, thus 
escaping detection but nevertheless aiding in growth of the 
microvasculature. Monocytes-macrophages adhering to and 
invading vascular wall segments of growing collateral ves- 
se13 are very frequently observed in developing canine but 
not in porcine collateral vessels. The role of these cells that 
are producers of the angiogenic tumor necrosis factor 
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(TNF-ol) is, therefore, not entirely clear. The problem may 
be one of detection: large canine collateral vessels were 
longitudinally slit and the intimal surface was viewed in the 
scanning electron microscope. What appears numerous in 
low power scanning electron microscopy is much more 
difficult to detect in thin transverse sections in the transmis- 
sion electron microscope. Because no large collateral ves- 
sels are produced in the porcine heart, there is only a small 
chance of detecting macrophages in small vessels. We are 
not aware of the existence of macrophage-specific antibodies 
against porcine macrophages (antihuman macrophage anti- 
bodies do not cross-react). Availability of such antibodies 
would aid in the detection of macrophages in tissue because 
of the fluorescence labeling of the secondary antibody. 
Growth Factors Can Be Isolated From 
Normal Myocardium 
Fibroblast growth factor. The observation of vascular 
growth initiated by ischemia leads us to search for a mitogen. 
The idea of employing the “grind and find” approach on the 
protein level using only tissue with observable vascular 
growth was quite discouraging because of the large number 
of experimental animals needed. On the other hand, vascular 
mitogens had been discovered in the normal bovine brain at 
times when no vascular growth takes place. Beta-endothelial 
cell growth factor, its truncated form acidic fibroblast growth 
factor and its 35% homologue basic fibroblast growth factor 
were isolated from brain (22) using heparin affinity chroma- 
tography. We applied this method in slightly modified form 
to the normal heart, and were able to extract, purify and 
sequence acidic and basic fibroblast growth factor and its 
truncated form, angiogenetic fibroblast growth factor (16). 
By proteolytic cleavage of the beta-endothelial cell growth 
factor, we showed species differences in molecular compo- 
sition and minor amino acid sequence variations. 
The mitogen receptor barrier in the extracellular matrix. 
The presence of strong mitogens in the normal heart with no 
detectable vascular growth would suggest that a barrier 
normally exists between the mitogen and its receptor. Such 
a barrier may be the extracellular matrix in which the 
heparin-binding growth factors are believed to be stored. 
This hypothesis remains uncertain because the gene struc- 
ture of the fibroblast growth factors does not show a prepro- 
form (that is, a sequence coding for a signal peptide that 
enables the hormone to cross the cell membrane on its way 
out of the cell). With other tissue hormones that occupy 
receptors on the outer envelope of the cell membrane, these 
sequences are known and are cleaved off by specific pro- 
teases when the protein complex enters the domain of the 
plasma membrane. The absence of this signal sequence 
makes it difficult to understand how the fibroblast growth 
factors can get into the extracellular matrix. This problem is 
not unique to the fibroblast growth factors: two other growth 
factors also do not have signal peptides (that is, interleukin 
and platelet-derived endothelial cell growth factor). There- 
fore, some investigators (23,24) believe that the fibroblast 
growth factors will leave the cell only after significant 
damage (as in ischemia). The free hormone can then occupy 
receptors of surviving cells in the region that will then 
respond with mitosis. 
Localization of fibroblast growth factor. The microscopic 
localization of acidic fibroblast growth factor is difficult 
because of the low concentrations of this hormone in cells. 
After preincubation of cells with acidic fibroblast growth 
factor and with the use of residual light amplification, a 
localization near the nucleolus was found. Using monoclonal 
antibodies that we developed against acidic fibroblast growth 
factor, a similar localization was found in cultured endothe- 
lial cells but without preincubation. To date, we have not 
been able to show enhanced expression of the protein in the 
collateralized heart. However, this may be due to the fact 
that the amounts produced with enhanced expression are 
still too low for detection with immunohistochemistry. 
Growth Factor Transcription Is Enhanced in 
Collateralized Myocardium 
Transcription of growth factor genes. A more sensitive 
and specific way to study growth factor expression is to 
measure the transcription of the growth factor genes. This is 
done by extraction of messenger ribonucleic acid (RNA) 
from normal and collateralized myocardial regions, gel elec- 
trophoresis of the RNA and blotting of the RNA on filter 
membranes where it is “probed” with radioactively labeled 
cDNAs for known growth factors (Northern blot hybridiza- 
tion). Under physiologic conditions in normal hearts, mes- 
senger RNA for acidic fibroblast growth factor cannot be 
detected. With progressive coronary stenosis and induced 
collateralization, acidic fibroblast growth factor transcripts 
are detectable by Northern blot hybridization. We further 
investigated the transcription of the angiogentic peptide 
TGF-P and found enhanced transcription also in collateral- 
ized tissue. Another way to study transcription is to amplify 
known segments of transcripts after selective reverse tran- 
scription with the polymerase chain reaction. Because of the 
extreme sensitivity of this method, we found transcription of 
TGF-/3 in the control as well as in the collateralized region of 
the porcine heart. The polymerase chain reaction is difficult 
to calibrate, and we interpret the differences between the 
Northern blots and polymerase chain reaction as enhanced 
expression of TGF-/3 (in collateralized tissue detectable by 
Northern blot hybridization) that shows a basal level of 
transcription (detectable by polymerase chain reaction) in 
normal tissue. 
Localization of growth factor transcription. Northern blot 
hybridization and polymerase chain reaction are able to 
show whether there is transcription and how much. How- 
ever, these methods cannot show where transcription oc- 
curs. This can be studied by in situ hybridization where 
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radioactive cDNA is hybridized to its complementary mes- 
senger RNA in a tissue section. In situ hybridization is a 
complex technique, and special problems exist with the 
cDNA for acidic fibroblast growth factor because it has 
GC-rich sequences that tend to form “hairpins” and conse- 
quently do not hybridize with messenger RNA. We collab- 
orated with Kandolf (Max Planck Institute for Biochemis- 
try), who was able to detect acidic fibroblast growth factor 
transcripts (but not basic fibroblast growth factor tran- 
scripts) only in vascular walls in collateralized porcine 
myocardium and not in normal myocardium. 
Collateral Vessel Growth Is the Result of a 
Growth Factor Cascade 
Resistance to ischemia of microvascular endothelium ver- 
sus cardiac monocytes. The detection of acidic fibroblast 
growth factor transcripts over blood vessel walls in collater- 
alized porcine hearts with a heterologous (human) cDNA 
probe came as a surprise because we had assumed that the 
ischemic cardiac myocytes would produce the mitogen. In 
heart tissue, mainly the cardiac myocytes will react to a 
shortage of oxygen as it occurs with progressive stenosis. 
Vascular tissue will probably never become ischemic in the 
canine heart, not even with acute coronary occlusion, be- 
cause residual blood flow (arterial in nature) is more than 
sufficient to nourish vascular cells that are in close contact 
with the arterial blood and that exhibit only about 10% of the 
oxygen requirements of cardiac myocytes. Our own ultra- 
structural observations (25) showed that, although coronary 
microvascular endothelium reacts visibly to ischemia, it is 
actually more ischemia-resistant than myocytes and recov- 
ers faster after reperfusion. in experimental myocardial 
infarction, capillaries but not myocytes survive, a result that 
gives the false impression of increased capillary density. In 
short, it is likely that tissue ischemia is not sensed mainly by 
microvascular endothelium, but rather by cardiac myocytes. 
The sequence of events. Thus, the finding of a transcript in 
vascular wall shows the existence of a sequence of events: 
the ischemic myocyte signals to the microvascular environ- 
ment that it should enter the cell cycle of mitosis. After that, 
endothelial and smooth muscle cells must communicate for 
the right balance of growth between these cells. The se- 
quence of events may be as follows: 
Progressive coronary stenosis leads to episodes of isch- 
emia, depending on the degree of physical activity. 
Ischemic episodes lead to the expression of a hitherto not 
identified ischemia-related mitogen activator. 
After binding to a microvascular cell receptor, ischemia- 
related mitogen activator initiates tibroblast growth factor 
transcription. 
Increased fibroblast growth factor transcription starts the 
cell cycle leading to mitosis in endothelial cells. 
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Stimulated endothelial cells may produce platelet-derived 
growth factor that leads to smooth muscle cell mitosis. 
Finally, the differentiation factor TGF-P is produced to 
ensure specialized functions. 
Stimulated endothelium may also cause monocytes and 
platelets to adhere and unload and to produce additional 
growth factor or factors such as the angiogenetic peptide 
tumor necrosis factor. 
The Ischemia-Related Mitogen-Activator 
Resists (So Far) Detection 
If experimental conditions with progressive coronary 
occlusion are so timed that ischemia-related mitogen activa- 
tor is present exclusively in the region at risk of infarction, 
the strategy of subtractive cloning is the most powerful 
approach for isolating an unknown peptide for which no 
structural information is available and that is probably 
extremely difficult to isolate because of its elusive nature. 
The peptide may also be rapidly destroyed locally and may 
not survive the unavoidably harsh isolation procedures. 
Subtractive cloning. This method requires only the isola- 
tion of myocardial messenger RNA from the area of begin- 
ning collateralization and from a normal area of the same 
heart. The experimental area messenger RNA is reverse 
transcribed, and the resulting cDNA is hybridized with the 
messenger RNA from the control side: unique single- 
stranded cDNA coding for ischemia-related mitogen 
activator (its minus strand) does not find a complementary 
messenger RNA structure in the control side and remains 
single-stranded. After separation of single-stranded DNA 
from double-stranded DNA by hydroxyapatite, the plus 
strand is synthesized and the double-stranded cDNA is then 
cloned and sequenced. It is predictable that the two myo- 
cardial regions differ by more than one molecule or factor. 
The power of the method is that theoretically only one heart 
is needed and no previous information is required as to the 
nature of the unknown peptide. 
Is Ischemia-Related Mitogen Activator 
Only the Concerted Action of 
Lactate, pH, Adenosine and 
Nicotinamide-Adenine Dinucleotide? 
Role of adenosine and nicotinic acid. Ischemia, the only 
condition known to stimulate collateral vessel growth, is 
usually viewed in terms of high energy phosphate break- 
down and lactate production. Adenosine, a transient break- 
down product of ATP, is a potent vasodilator; it is also a 
product of nicotinamide-adenine dinucleotide cleavage, as is 
nicotinic acid. Adenosine and nicotinic acid showed some 
indirect (nonmitogenic) angiogenic activity in some labora- 
tories (26). whereas a direct mitogenic activity of adenosine 
was found by others (27) in cultures of bovine microvascular 
coronary endothelium. Long-term infusion of adenosine into 
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rabbits has been reported to increase myocardial capillary 
density (28), and similar findings were reported after infusion 
of dipyridamole (an adenosine potentiator) in rats (29). From 
these observations, a relatively strong case can be con- 
structed for purine and pyrimidine nucleosides as ischemia- 
related mitogen activators in small coronary blood vessels. 
Despite the suggestive evidence, no proof is available that 
adenosine and nicotinic acid induce collateral vessel growth. 
Ingestion of relatively high doses of dipyridamole in dogs did 
not lead to changes in peripheral coronary pressure and 
collateral blood flow (unpublished observations). 
Our own studies (30) and those of others (31) show that 
vascular endothelium has a high capacity to dephosphorylate 
nucleotides by exonucleotidases and to remove circulating 
adenosine by either phosphorylation or, at higher intracellu- 
lar concentrations, by deamination. These functions are 
important for the maintenance of hemostasis and thrombol- 
ysis and the removal of chemical debris from lysed erythro- 
cytes and platelet thrombi. The high capacity of the endo- 
thelium to inactivate adenosine contrasts with the proposed 
role of adenosine as a mitogen activator. 
Implications. The construction of a very complex tissue 
like a new small coronary artery is probably regulated by a 
genetic blueprint rather than by haphazard availability of 
metabolic waste. Accordingly, we continue to believe in the 
orchestrated interplay of growth factors, for which the first 
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